Modal ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	2
70	広範脊柱管狭窄症	1

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2200059588	2022-06-01	2022-05-04	Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machine learning	Analysis of speech disorders in patients with Parkinson's disease based on speech signals and machine learning	Parkinson's Disease	Gold Standard:Parkinson's speech features that can be used for recognition ;Index test:Extract the multi-modal speech features of Parkinson's patients using the developed speech signal processing algorithm ;	Provincial Government Hospital in Jiangsu Province	NULL	Pending	18	75	Both	Target condition:200;Difficult condition:0	N/A	China
2	EUCTR2010-019396-29-IT (EUCTR)	18/05/2010	05/03/2012	Levodopa and Pramipexole dministration modalities in patients affected by parkinson desease.	Levodopa Administration Modalities and Pramipexole in Parkinson's Disease (LAMP-PD study) A multicenter, randomized, four parallel groups, active-controlled, open-label study to evaluate the risk of dyskinesia in early PD. - LAMP-PD	Patients with idiopathic Parkinson's Disease.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: COMTAN INN or Proposed INN: Entacapone INN or Proposed INN: Levodopa and decarboxylase inhibitor Trade Name: STALEVO*100CPR 50/12,5/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor Trade Name: STALEVO*100CPR 100/25/200MG INN or Proposed INN: Levodopa, decarboxylase inhibitor and COMT inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor INN or Proposed INN: Levodopa and decarboxylase inhibitor	AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO-VITTORIO EMANUELE	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

70. 広範脊柱管狭窄症

---

臨床試験数 : 95 /  薬物数 : 169 - (DrugBank : 61) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 90

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03088306 (ClinicalTrials.gov)	July 1, 2017	22/2/2017	Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients	Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery	Lumbar Spinal Stenosis;Lumbar Spinal Instability;Lumbar Spine Degeneration	Drug: Standard analgesia use [Oxygen];Drug: Standard analgesia use [Hydromorphone];Drug: Standard analgesia use [Volatile Anesthesia];Drug: Standard analgesia use [Fentanyl];Drug: Multi-modal pain management [Acetaminophen + Gabapentin];Drug: Multi-modal pain management [Fentanyl];Drug: Multi-modal pain management [Intravenous Ketamine];Drug: Multi-modal pain management [Valium + Gabapentin]	Johns Hopkins University	North American Spine Society	Completed	18 Years	100 Years	All	49	Early Phase 1	United States